Quality Criteria for the Webpages of the Paul-Ehrlich-Institut (PEI)
The Paul-Ehrlich-Institut is a Federal German authority domiciled in Langen which is close to Frankfurt am Main. Its research and medicines control activities promote the quality, efficacy and safety of biomedicinal products. Its duties are regulated by Federal law: the Errichtungsgesetz (Law Establishing a Senior Federal Authority), the Arzneimittelgesetz (German Medicinal Products Act), the Infektionsschutzgesetz (Infection Protection Act), the Transfusionsgesetz (Transfusion Act), and the Tiergesundheitsgesetz (TierGesG, Animal Diseases Act) etc. Other responsibilities of the PEI derive from EU law.
The Paul-Ehrlich-Institut reports to the Bundesministerium für Gesundheit (BMG) (Federal Ministry of Health and Social Security). The details of its revenue and expenditure may be found in Chapter 1515 of the Federal Budget Statement of 2016, (Bundeshaushaltsplan 2016, Kapitel 1515). Its budget is audited by the BMG and the Bundesrechnungshof (German Federal Court of Auditors). The institute’s revenue essentially consists of fees levied for the performance of its duties (Statutory Cost Regulation of the PEI, Statutory Cost Regulation on Animal Vaccines). Additional revenue comes from the performance of official tasks assigned by the European Medicines Agency EMA and other authorities in the field of public health (e.g. other licensing authorities).
For tax purposes, the testing laboratory for in vitro diagnostic medical devices, PEI-IVD, is treated as a commercial business. It receives its revenue from services provided to notified bodies - as they are known pursuant to European medical devices law. PEI-IVD charges for its services on the basis of a price list. PEI-IVD does not operate on a profit-making basis.
Research at the Paul-Ehrlich-Institut receives financial support from external institutions such as the European Commission and the Deutsche Forschungsgemeinschaft (DFG) (German Research Foundation). For an overview, please refer to the Research Grants page.
The Paul-Ehrlich-Institut does not engage in any advertising activities or receive any revenue from advertising.
Our Target Groups
Our webpages provide information on our duties and activities. The Paul-Ehrlich-Institut’s target groups include:
- Patients and Consumers
- Pharmaceutical Manufacturers and Applicants for Marketing Authorisations
- Physicians and Pharmacists
- Companies and institutions subject to reporting requirements pursuant to Section 21 German Transfusion Act
Visitors to our site may contact the Paul-Ehrlich-Institut by clicking the Contacts button.
Quality Criteria for our Internet Content
All information published by the Paul-Ehrlich-Institut is consistent with the current state of scientific knowledge and has undergone specialist verification by the author and at least one member of the editorial board in accordance with the "dual control" principle. The content is then published on the web by our internet editors.
The quality of information in the field of health and research depends on how up-to-date such information is. Our pages therefore indicate both the date on which the information was first compiled and the time of the latest update.
The information on our webpages is designed to support the relationship between the patient and the physician, not to replace it. We provide information for both target groups.
The information on this page fulfils the requirements of the Health on Net Initiative (HON), a renowned organisation for the quality assurance of health information.
We at the Paul-Ehrlich-Institut attach great importance to integrate disabled persons into our working life. We have therefore done our utmost to implement the Barrierefreie Informationstechnik-Verordnung (BITV) (Statutory Regulation on Accessible Information Technology of the Federal Republic of Germany).